InterventionsHuman trial

Effect of the Dual GLP-1/GIP Receptor Agonist Tirzepatide on Circulating Proteins Associated with ESKD Risk in Patients with Type 2 Diabetes

ADA Scientific Sessions 2026 Abstract

The paper

Eiichiro Satake, Sok Cin Tye, Imre Pavo,

Anna Nowak-Szwed, Lenden M. Bowsman, Jonathan Wilson, Fergus Fleming, Kevin L. Duffin,

Andrzej Krolewski

Boston

ADA Scientific Sessions 2026 Abstract · 5 Jun 2026

Presented at ADA Scientific Sessions 2026 · Poster 1395-P

doi.org/10.2337/db26-1395-p

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity
The New England Journal of Medicine · 4 Oct 2026
Semaglutide may protect kidneys by reducing vascular resistance
Nature Medicine · 4 Oct 2026